Last reviewed · How we verify

Adrenal cortical hypofunction — Treatment Landscape & Competitive Intelligence

Adrenal cortical hypofunction (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Adrenal cortical hypofunction, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Cortrosyn tetracosactide Amphastar Pharms Inc Adrenocorticotropic Hormone [EPC] Melanocortin receptor 4 1970-01-01
Depo-Medrol METHYLPREDNISOLONE ACETATE Pfizer Corticosteroid Glucocorticoid receptor 1959-01-01
Decadron dexamethasone Generic (originally Merck) Corticosteroid [EPC] Annexin A1, Interleukin-4, Androgen receptor 1958-10-30
Medrol methylprednisolone Generic (originally Upjohn/Pfizer) Glucocorticoid (corticosteroid) Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor 1957-10-01
Prelone prednisolone Generic (originally Schering) Glucocorticoid (corticosteroid) Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1 1955-01-01
Deltasone prednisone Generic (originally Schering) Corticosteroid [EPC] Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor 1955-01-01
Solu-Cortef hydrocortisone succinate Pfizer Corticosteroid Glucocorticoid receptor 1955-01-01
Cortef hydrocortisone Generic (originally Merck/Upjohn) Corticosteroid [EPC] Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible 1952-01-01
Cortifoam HYDROCORTISONE ACETATE Pfizer Corticosteroid Corticosteroid-binding globulin 1951-01-01
prednison prednison Wen Zhang Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 4 drugs in Adrenal cortical hypofunction
  2. Pfizer · 3 drugs in Adrenal cortical hypofunction
  3. Generic (originally Schering) · 2 drugs in Adrenal cortical hypofunction
  4. Generic (originally Merck/Upjohn) · 1 drug in Adrenal cortical hypofunction
  5. Generic (originally Upjohn/Pfizer) · 1 drug in Adrenal cortical hypofunction
  6. Hannover Medical School · 1 drug in Adrenal cortical hypofunction
  7. Leiden University Medical Center · 1 drug in Adrenal cortical hypofunction
  8. University of Zurich · 1 drug in Adrenal cortical hypofunction
  9. Wen Zhang · 1 drug in Adrenal cortical hypofunction
  10. Amphastar Pharms Inc · 1 drug in Adrenal cortical hypofunction
  11. Generic (originally Merck) · 1 drug in Adrenal cortical hypofunction

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Adrenal cortical hypofunction:

Cite this brief

Drug Landscape (2026). Adrenal cortical hypofunction — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/adrenal-cortical-hypofunction. Accessed 2026-06-11.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing